ASX - By Stock
|
ZLD |
Re:
Summary
|
|
Mcdunk
|
37 |
17K |
0 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
37
|
17K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Summary
|
|
Mcdunk
|
37 |
17K |
6 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
37
|
17K
|
6
|
|
ASX - By Stock
|
ZLD |
Re:
Levin health
|
|
Mcdunk
|
28 |
8.9K |
2 |
06/01/24 |
06/01/24 |
ASX - By Stock
|
28
|
8.9K
|
2
|
|
ASX - By Stock
|
GFS |
Re:
Still Registered
|
|
Mcdunk
|
13 |
5.2K |
0 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
13
|
5.2K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Levin health
|
|
Mcdunk
|
28 |
8.9K |
0 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
28
|
8.9K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Levin health
|
|
Mcdunk
|
28 |
8.9K |
1 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
28
|
8.9K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Levin health
|
|
Mcdunk
|
28 |
8.9K |
1 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
28
|
8.9K
|
1
|
|
ASX - By Stock
|
ZLD |
Levin health
|
|
Mcdunk
|
28 |
8.9K |
0 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
28
|
8.9K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: 2023 Annual General Meeting Presentation
|
|
Mcdunk
|
12 |
5.4K |
0 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
12
|
5.4K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: 2023 Annual General Meeting Presentation
|
|
Mcdunk
|
12 |
5.4K |
5 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
12
|
5.4K
|
5
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Annual Report to shareholders
|
|
Mcdunk
|
14 |
5.7K |
1 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
14
|
5.7K
|
1
|
|
ASX - By Stock
|
GFS |
Re:
Still Registered
|
|
Mcdunk
|
13 |
5.2K |
0 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
13
|
5.2K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Appendix 4C Cash Flow Report
|
|
Mcdunk
|
6 |
3.2K |
8 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
6
|
3.2K
|
8
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
2 |
07/06/23 |
07/06/23 |
ASX - By Stock
|
217
|
70K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
7 |
07/06/23 |
07/06/23 |
ASX - By Stock
|
217
|
70K
|
7
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
8 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
217
|
70K
|
8
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
6 |
05/06/23 |
05/06/23 |
ASX - By Stock
|
217
|
70K
|
6
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
3 |
01/06/23 |
01/06/23 |
ASX - By Stock
|
217
|
70K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
4 |
01/06/23 |
01/06/23 |
ASX - By Stock
|
217
|
70K
|
4
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Proposed issue of securities - ZLD
|
|
Mcdunk
|
2 |
1.0K |
1 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
2
|
1.0K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira Non-Executive Director Appointed
|
|
Mcdunk
|
2 |
1.3K |
1 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
2
|
1.3K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
4 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
217
|
70K
|
4
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
3 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
217
|
70K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
|
|
Mcdunk
|
217 |
70K |
10 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
217
|
70K
|
10
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
17 |
6.0K |
3 |
29/05/23 |
29/05/23 |
ASX - By Stock
|
17
|
6.0K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
17 |
6.0K |
4 |
29/05/23 |
29/05/23 |
ASX - By Stock
|
17
|
6.0K
|
4
|
|
ASX - By Stock
|
ZLD |
Re:
Autism
|
|
Mcdunk
|
9 |
3.1K |
0 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
9
|
3.1K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Autism
|
|
Mcdunk
|
9 |
3.1K |
1 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
9
|
3.1K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Appendix 4C Cash Flow Report
|
|
Mcdunk
|
7 |
2.3K |
5 |
27/04/23 |
27/04/23 |
ASX - By Stock
|
7
|
2.3K
|
5
|
|
ASX - By Stock
|
ZLD |
Re:
Autism
|
|
Mcdunk
|
9 |
3.1K |
6 |
05/04/23 |
05/04/23 |
ASX - By Stock
|
9
|
3.1K
|
6
|
|
ASX - By Stock
|
ZLD |
Autism
|
|
Mcdunk
|
9 |
3.1K |
5 |
05/04/23 |
05/04/23 |
ASX - By Stock
|
9
|
3.1K
|
5
|
|
ASX - By Stock
|
ZLD |
Cannabis in a capsule
|
|
Mcdunk
|
4 |
2.1K |
7 |
29/03/23 |
29/03/23 |
ASX - By Stock
|
4
|
2.1K
|
7
|
|
ASX - By Stock
|
CPH |
Re:
Ann: Censure of Creso Pharma Limited
|
|
Mcdunk
|
28 |
16K |
9 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
28
|
16K
|
9
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
13 |
4.2K |
2 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
13
|
4.2K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira HOPE 1 SPV Investor Presentation
|
|
Mcdunk
|
9 |
3.0K |
2 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
9
|
3.0K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Initial Director's Interest Notice
|
|
Mcdunk
|
5 |
2.4K |
2 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
5
|
2.4K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira HOPE 1 SPV Investor Briefing Webinar
|
|
Mcdunk
|
2 |
889 |
6 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
2
|
889
|
6
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira Executive Director Appointed
|
|
Mcdunk
|
8 |
2.7K |
2 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
8
|
2.7K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira Executive Director Appointed
|
|
Mcdunk
|
8 |
2.7K |
3 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
8
|
2.7K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
20 |
5.7K |
7 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
20
|
5.7K
|
7
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
20 |
5.7K |
3 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
20
|
5.7K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
20 |
5.7K |
5 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
20
|
5.7K
|
5
|
|
ASX - By Stock
|
CPH |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
30 |
9.5K |
2 |
16/02/23 |
16/02/23 |
ASX - By Stock
|
30
|
9.5K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: ZLD secures US$8.6 million funding for HOPE 1 US FDA trials
|
|
Mcdunk
|
22 |
5.4K |
2 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
22
|
5.4K
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: ZLD secures US$8.6 million funding for HOPE 1 US FDA trials
|
|
Mcdunk
|
22 |
5.4K |
3 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
22
|
5.4K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
12 |
3.8K |
3 |
13/02/23 |
13/02/23 |
ASX - By Stock
|
12
|
3.8K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
12 |
3.8K |
1 |
13/02/23 |
13/02/23 |
ASX - By Stock
|
12
|
3.8K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
Mcdunk
|
12 |
3.8K |
6 |
13/02/23 |
13/02/23 |
ASX - By Stock
|
12
|
3.8K
|
6
|
|
ASX - By Stock
|
GFS |
Re:
Still Registered
|
|
Mcdunk
|
13 |
5.2K |
3 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
13
|
5.2K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Cash v Potential CR v 40m CPH shares v Listing Rules
|
|
Mcdunk
|
2 |
942 |
0 |
06/02/23 |
06/02/23 |
ASX - By Stock
|
2
|
942
|
0
|
|